![Barbara Coles Bsc (Hons), MPhil](https://profiles-cardiff.imgix.net/attachments/4140?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Trosolwyg
Rwy'n unigolyn dibynadwy a rhagweithiol gyda chefndir ymchwil eang a phrofiad cynhwysfawr mewn rheoli prosiectau, cyflwyno gweithredol, rheoli tîm ac arloesi trwy gyd-ddatblygu ac ymgysylltu. Rwy'n cyflwyno cydweithrediadau a rhwydweithiau gwaith sefydledig ar draws y diwydiant, y sector cyhoeddus a'r trydydd sector.
Roeddwn i'n rheoli Cyflymydd Arloesi Clinigol Caerdydd, rhaglen Cyflymu ERDF (2018-2023). Rwyf hefyd yn cefnogi gweithgareddau rheoli prosiectau, datblygu strategol, a gweithredu CIH, gan ddarparu'r prif gyswllt rhwng Prifysgol Caerdydd a phartneriaid. Mae Barbara yn cefnogi mentrau yn y Bartneriaeth Arloesi Clinigol rhwng Prifysgol Caerdydd a Bwrdd Iechyd Prifysgol Caerdydd a'r Fro, ac mae hon yn biblinell hanfodol ar gyfer gweithgareddau a phrosiectau arloesi clinigol. Barbara yw arweinydd arloesi a busnes ym Mhentre Awel - menter Iechyd a Lles yn Llanelli.
Cyhoeddiad
2014
- Fielding, C. A. et al. 2014. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 40(1), pp. 40-50. (10.1016/j.immuni.2013.10.022)
2013
- Raby, A. et al. 2013. Targeting the TLR co-receptor CD14 with TLR2-derived peptides modulates immune responses to pathogens. Science Translational Medicine 5(185), article number: 185ra64. (10.1126/scitranslmed.3005544)
2011
- Clark, S. R. et al. 2011. Esterified eicosanoids are acutely generated by 5-lipoxygenase in primary human neutrophils and in human and murine infection. Blood 117(6), pp. 2033-2043. (10.1182/blood-2010-04-278887)
- Raby, A. et al. 2011. TLR activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2. European Journal of Immunology 41(9), pp. 2741-2752. (10.1002/eji.201041350)
2010
- Coles, B., Colmont, C. S., Fielding, C. A., Kift-Morgan, A., Hams, E., Topley, N. and Jones, S. A. 2010. Local manipulation of IL-6 trans-signaling therapeutically enhances anti-microbial host defense [Abstract]. Cytokine 52(1-2), pp. 80-81. (10.1016/j.cyto.2010.07.335)
2009
- Raby, A. et al. 2009. Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. The Journal of Immunology 183(1), pp. 506-517. (10.4049/jimmunol.0802909)
- Maskrey, B. H. et al. 2009. Activated platelets and monocytes generate four hydroxyphosphatidylethanolamines via lipoxygenase [Addition]. Journal of Biological Chemistry 284(37), pp. 25460. (10.1074/jbc.A611776200)
- Morgan, A. H. et al. 2009. Phosphatidylethanolamine-esterified eicosanoids in the mouse: tissue localization and inflammation-dependent formation in Th-2 disease. Journal of Biological Chemistry 284(32), pp. 21185-21191. (10.1074/jbc.M109.021634)
2008
- Morton, J. et al. 2008. Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFN -dependent iNOS expression in the vasculature of healthy mice. Blood 111(10), pp. 5187-5194. (10.1182/blood-2007-10-117283)
- Coles, B., Wilton, L. A. K., Good, M. A., Chapman, P. F. and Wann, K. T. 2008. Potassium channels in hippocampal neurones are absent in a transgenic but not in a chemical model of Alzheimer's disease. Brain Research 1190, pp. 1-14. (10.1016/j.brainres.2007.10.071)
2007
- Coles, B., Fielding, C. A., Rose-John, S., Scheller, J., Jones, S. A. and O'Donnell, V. B. 2007. Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. American Journal of Pathology 171(1), pp. 315-325. (10.2353/ajpath.2007.061078)
2006
- Anning, P. B. et al. 2006. Nitric Oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors. Blood 108(13), pp. 4059-4062. (10.1182/blood-2006-02-005330)
2005
- Williams, P. C. et al. 2005. In vivo aspirin supplementation inhibits nitric oxide consumption by human platelets. Blood 106(8), pp. 2737-2743. (10.1182/blood-2005-02-0664)
2004
- Coffey, M. J., Coles, B., Locke, M., Bermudez-Fajardo, A., Williams, P. C., Jarvis, G. E. and O'Donnell, V. B. 2004. Interactions of 12-lipoxygenase with phospholipase A2 isoforms following platelet activation through the glycoprotein VI collagen receptor. FEBS Letters 576(1-2), pp. 165-168. (10.1016/j.febslet.2004.09.007)
- Coffey, M. J., Jarvis, G. E., Gibbins, J. M., Coles, B., Barrett, N. E., Wylie, O. R. and O'Donnell, V. B. 2004. Platelet 12-lipoxygenase activation via glycoprotein VI: involvement of multiple signaling pathways in agonist control of H(P)ETE synthesis. Circulation Research 94(12), pp. 1598-1605. (10.1161/01.RES.0000132281.78948.65)
2002
- Coles, B., Bloodsworth, A., Clark, S. R., Lewis, M. J., Cross, A. R., Freeman, B. A. and O'Donnell, V. B. 2002. Nitrolinoleate inhibits superoxide generation, degranulation, and integrin expression by human neutrophils: novel antiinflammatory properties of nitric oxide-derived reactive species in vascular cells. Circulation Research 91(5), pp. 375-381. (10.1161/01.RES.0000032114.68919.EF)
2001
- Coffey, M. J. et al. 2001. Catalytic consumption of nitric oxide by 12/15- lipoxygenase: inhibition of monocyte soluble guanylate cyclase activation. Proceedings of the National Academy of Sciences of the United States of America (PNAS) ISSN 1091-6490 98(14), pp. 8006-8011. (10.1073/pnas.141136098)
Erthyglau
- Fielding, C. A. et al. 2014. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 40(1), pp. 40-50. (10.1016/j.immuni.2013.10.022)
- Raby, A. et al. 2013. Targeting the TLR co-receptor CD14 with TLR2-derived peptides modulates immune responses to pathogens. Science Translational Medicine 5(185), article number: 185ra64. (10.1126/scitranslmed.3005544)
- Clark, S. R. et al. 2011. Esterified eicosanoids are acutely generated by 5-lipoxygenase in primary human neutrophils and in human and murine infection. Blood 117(6), pp. 2033-2043. (10.1182/blood-2010-04-278887)
- Raby, A. et al. 2011. TLR activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2. European Journal of Immunology 41(9), pp. 2741-2752. (10.1002/eji.201041350)
- Coles, B., Colmont, C. S., Fielding, C. A., Kift-Morgan, A., Hams, E., Topley, N. and Jones, S. A. 2010. Local manipulation of IL-6 trans-signaling therapeutically enhances anti-microbial host defense [Abstract]. Cytokine 52(1-2), pp. 80-81. (10.1016/j.cyto.2010.07.335)
- Raby, A. et al. 2009. Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. The Journal of Immunology 183(1), pp. 506-517. (10.4049/jimmunol.0802909)
- Maskrey, B. H. et al. 2009. Activated platelets and monocytes generate four hydroxyphosphatidylethanolamines via lipoxygenase [Addition]. Journal of Biological Chemistry 284(37), pp. 25460. (10.1074/jbc.A611776200)
- Morgan, A. H. et al. 2009. Phosphatidylethanolamine-esterified eicosanoids in the mouse: tissue localization and inflammation-dependent formation in Th-2 disease. Journal of Biological Chemistry 284(32), pp. 21185-21191. (10.1074/jbc.M109.021634)
- Morton, J. et al. 2008. Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFN -dependent iNOS expression in the vasculature of healthy mice. Blood 111(10), pp. 5187-5194. (10.1182/blood-2007-10-117283)
- Coles, B., Wilton, L. A. K., Good, M. A., Chapman, P. F. and Wann, K. T. 2008. Potassium channels in hippocampal neurones are absent in a transgenic but not in a chemical model of Alzheimer's disease. Brain Research 1190, pp. 1-14. (10.1016/j.brainres.2007.10.071)
- Coles, B., Fielding, C. A., Rose-John, S., Scheller, J., Jones, S. A. and O'Donnell, V. B. 2007. Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. American Journal of Pathology 171(1), pp. 315-325. (10.2353/ajpath.2007.061078)
- Anning, P. B. et al. 2006. Nitric Oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors. Blood 108(13), pp. 4059-4062. (10.1182/blood-2006-02-005330)
- Williams, P. C. et al. 2005. In vivo aspirin supplementation inhibits nitric oxide consumption by human platelets. Blood 106(8), pp. 2737-2743. (10.1182/blood-2005-02-0664)
- Coffey, M. J., Coles, B., Locke, M., Bermudez-Fajardo, A., Williams, P. C., Jarvis, G. E. and O'Donnell, V. B. 2004. Interactions of 12-lipoxygenase with phospholipase A2 isoforms following platelet activation through the glycoprotein VI collagen receptor. FEBS Letters 576(1-2), pp. 165-168. (10.1016/j.febslet.2004.09.007)
- Coffey, M. J., Jarvis, G. E., Gibbins, J. M., Coles, B., Barrett, N. E., Wylie, O. R. and O'Donnell, V. B. 2004. Platelet 12-lipoxygenase activation via glycoprotein VI: involvement of multiple signaling pathways in agonist control of H(P)ETE synthesis. Circulation Research 94(12), pp. 1598-1605. (10.1161/01.RES.0000132281.78948.65)
- Coles, B., Bloodsworth, A., Clark, S. R., Lewis, M. J., Cross, A. R., Freeman, B. A. and O'Donnell, V. B. 2002. Nitrolinoleate inhibits superoxide generation, degranulation, and integrin expression by human neutrophils: novel antiinflammatory properties of nitric oxide-derived reactive species in vascular cells. Circulation Research 91(5), pp. 375-381. (10.1161/01.RES.0000032114.68919.EF)
- Coffey, M. J. et al. 2001. Catalytic consumption of nitric oxide by 12/15- lipoxygenase: inhibition of monocyte soluble guanylate cyclase activation. Proceedings of the National Academy of Sciences of the United States of America (PNAS) ISSN 1091-6490 98(14), pp. 8006-8011. (10.1073/pnas.141136098)
Bywgraffiad
Barbara yw Rheolwr y Ganolfan Arloesi Clinigol (CIH) yn yr Ysgol Meddygaeth, Prifysgol Caerdydd. Mae'n cefnogi gweithgareddau rheoli prosiect cyffredinol, datblygu strategol a gweithredu CIH, gan ddarparu'r prif gyswllt rhwng Prifysgol Caerdydd a'r partneriaid Accelerate. Mae Barbara yn cefnogi mentrau yn y Bartneriaeth Arloesi Clinigol rhwng Prifysgol Caerdydd a Bwrdd Iechyd Prifysgol Caerdydd a'r Fro, ac mae hon yn biblinell hanfodol ar gyfer gweithgareddau a phrosiectau arloesi clinigol. Cwblhaodd Barbara ei MPhil ym Mhrifysgol Caerdydd gyda gyrfa ymchwil yn rhychwantu electroffisioleg sianeli potasiwm yn Alzheimer, ocsid nitrig mewn vasodilation a ceulo a llid (peritoneal a sepsis). Fel ymarferydd PRINCE 2, mae rheoli prosiectau wedi cynnwys gwobrau UTA Wellcome ac fel y Gweinyddwr Allbynnau ar gyfer Fframwaith Rhagoriaeth Ymchwil (REF 2014), Ysgol Meddygaeth.
Barbara yw rheolwr prosiect y Cyflymydd Arloesi Clinigol (CIA) yn yr Ysgol Meddygaeth, Prifysgol Caerdydd. Gyda chefnogaeth tîm ymroddedig o 17, mae'r CIA yn arbenigo mewn mabwysiadu prosiectau arloesol clinigol neu sy'n canolbwyntio ar gleifion trwy ddarparu cefnogaeth drwy arbenigedd y GIG, academaidd a menter, cydweithio ac ymgysylltu. Mae gwybodaeth wyddonol eang y tîm, ynghyd ag arbenigedd clinigol, iechyd, busnes, cyfreithiol, diwydiannol ac academaidd yn galluogi sgôpio, archwilio helaeth drwy wneud y mwyaf o botensial a datblygiad prosiectau i drawsnewid iechyd a gofal cleifion tra'n cefnogi twf economaidd Cymru.
Anrhydeddau a dyfarniadau
Mae fy hanes yn cael ei ddangos yn sgil cyflawni Cyflymu Caerdydd yn llwyddiannus a chael Gwobr Cyfraniad Eithriadol am y canlyniadau a gyflwynwyd - 2022
